Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

NYU Langone Health

Status and phase

Completed

Phase 4

Conditions

Coronary Artery Disease

Treatments

Drug: Ioxaglate

Drug: Iodixanol

Drug: Bivalirudin

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01848899

12-02409

Details and patient eligibility

About

The aim of this study is to determine how two different types of iodinated contrast media (CM) agents, low-osmolar ionic ioxaglate and iso-osmolar non-ionic iodixanol, affect specific markers of thrombogenesis and platelet function in patients undergoing coronary angiography, and if the use of bivalirudin, a direct thrombin inhibitor used during percutaneous coronary intervention (PCI), affects any contrast-related changes in thrombogenesis and platelet function.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must be more than 18 years of age
referred for coronary angiography and on dual anti-platelet therapy (aspirin and clopidogrel).

Exclusion criteria

on warfarin
on low molecular weight heparin within 12 hours of coronary angiography or unfractionated heparin with activated clotting time >150 at time of procedure -on cilostazol
on persantine
on non- steroidal anti-inflammatory medications (ibuprofen/motrin/advil, naproxen/aleve, indomethacin, sulindac, etodolac, diclofenac, celecoxib) within 72 hours of procedure
on prasugrel (not an exclusion criteria for ST-segment elevation myocardial infarction registry
undergoing coronary angiography via radial access
undergoing planned diagnostic coronary angiography only
unable to tolerate dual anti-platelet therapy
with known allergy to CM
received CM within 24 hours of coronary angiography
on dialysis
do not consent or are unable to give consent
are participating in another competing study.